BARDA seeks Amgen's Neupogen, Sanofi's Leukine for nuke attack countermeasures
This article was originally published in Scrip
The US Biomedical Advanced Research and Development Authority (BARDA) has contracted with Amgen and Sanofi to purchase the firms' leukocyte growth factors (LGFs) to add to the Strategic National Stockpile – a cache of drugs, vaccines and other medical products intended for use in a large-scale emergency, such as a natural disaster or terrorist attack – for use as medical countermeasures (MCMs) in the event of a radiological or nuclear incident.
You may also be interested in...
Partner Therapeutics takes on Sanofi's immunostimulant. Novartis transitions struggling Arzerra for compassionate use only outside the US, with compensation to Genmab, while Shire licenses I.V. immunoglobulin candidate from AB Biosciences.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.